Atea Pharmaceuticals
BOSTON, MA · Founded 2012 · CIK 0001593899 · Biotech · Public
Oral direct-acting antiviral small-molecule therapeutics for viral infections
ateapharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $156M
- 4 Form D · May 2020
- 76 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 23 granted · 17 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20132014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $12,000,000 | |
| Private capital raised | Form D · SEC | $20,829,775 | |
| Private capital raised | Form D · SEC | $27,599,934 | |
| Private capital raised | Form D · SEC | $107,499,941 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2029 | LIFORDI IMMUNOTHERAPEUTICS, INC. | — | — |
| 2030 | PROGENITOR INC. | — | — |
| 2031 | YALI BIOSCIENCES INC | — | — |
| 2032 | Atea Pharmaceuticals | — | $156M |
| 2033 | Orthogonal Biologics, Inc. | — | — |
| 2034 | CALIFIA BIO, INC. | — | — |
| 2035 | General Workings Inc. | — | $12M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Franklin BergerDirector
- Grigory BorisenkoDirector
- Gerald ChanDirector
- Bihua ChenDirector
- Isaac Cheng, M.D.Director
- Andrea CorcoranExecutive Officer
- Andrew Hack, M.D., Ph.D.Director
- Bruno LucidiDirector
- Bruce PolskyDirector
- Jean-Pierre SommadossiDirector · Executive Officer
- Jean-Pierre Sommadossi, Ph.D.Director · Executive Officer
- Fan YuDirector
- Frank YuDirector
- Evgeny ZatsevDirector
Patents
- Nucleotide Hemi-sulfate Salt For The Treatment Of Hepatitis C Virusgranted
- Advantageous Morphic Form Of AT-527 Hemi-sulfate Saltgranted
- Advantageous Anti-hcv Combination Therapyapplication
- Highly Active Compounds Against COVID-19granted
- Advantageous Morphic Form Of AT-527 Hemi-sulfate Saltapplication
- Advantageous Anti-hcv Combination Therapygranted
- Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENTapplication
- Nucleotide Hemi-sulfate Salt For The Treatment Of Hepatitis C Virusapplication
- Dosage Regimens For Treatment Of Dengue Infectionapplication
- Highly Active Compounds Against COVID-19granted
- BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED Purine Nucleotides For Hcv Treatmentgranted
- 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO Purine Nucleotides For Flavivirus Treatmentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.